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Psychostimulants as Cognitive Enhancers: The Prefrontal
Cortex, Catecholamines and Attention Deficit Hyperactivity
Disorder
Craig W. Berridge* and David M. Devilbiss
Department of Psychology, University of Wisconsin, Madison, WI
Abstract
Psychostimulants exert behavioral-calming and cognition-enhancing actions in the treatment of
attention deficit hyperactivity disorder (ADHD). Contrary to early views, extensive research
demonstrates that these actions are not unique to ADHD. Specifically, when administered at low
and clinically-relevant doses, psychostimulants improve a variety of behavioral and cognitive
processes dependent on the prefrontal cortex (PFC) in subjects with and without ADHD. Despite
the longstanding clinical use of these drugs, the neural mechanisms underlying their cognition-
enhancing/therapeutic actions have only recently begun to be examined. At behaviorally-
activating doses, psychostimulants produce large and widespread increases in extracellular levels
of brain catecholamines. In contrast, cognition-enhancing doses of psychostimulants exert
regionally-restricted actions, elevating extracellular catecholamine levels and enhancing neuronal
signal processing preferentially within the PFC. Additional evidence suggests a prominent role of
PFC α2- and D1 receptors in the behavioral and electrophysiological actions of low-dose
psychostimulants. These and other observations indicate a pivotal role of PFC catecholamines in
the cognition-enhancing and therapeutic actions of psychostimulants as well as other drugs used in
the treatment of ADHD. This information may be particularly relevant for the development of
novel pharmacological treatments for ADHD and other conditions associated with PFC
dysregulation.
Keywords
ADHD; Prefrontal Cortex; Cognition; Norepinephrine; Dopamine; Stimulants
Psychostimulants are a class of drugs most commonly associated with potent arousing and
behaviorally-activating actions as well as the significant potential for abuse (1–6).
Nonetheless, these drugs, particularly methylphenidate and amphetamine, are widely used to
calm behavior and improve cognitive function in children, adolescents and adults with
attention deficit hyperactivity disorder (ADHD; 7–13). These seemingly contradictory
actions of psychostimulants were initially thought to reflect unique and ‘paradoxical’ effects
in individuals with ADHD. However, subsequent work unambiguously demonstrated that
the cognition-enhancing and behavioral-calming actions of psychostimulants are not limited
to ADHD. Thus, when administered at low and clinically-relevant doses, psychostimulants
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improve behavioral and cognitive processes dependent on the prefrontal cortex (PFC) in
human subjects with and without ADHD (14–18). Moreover, these actions are not unique to
humans, having been documented in ‘normal’ animal subjects when administered at
clinically-relevant doses (i.e. doses that produce clinically-relevant plasma concentrations;
see Figure 1;5,6,19–22). The cognitive/therapeutic actions of low-dose psychostimulants are
observed acutely with neither pronounced tolerance nor sensitization associated with
extended treatment (8,23; except see 19). The ability of low-dose psychostimulants to
improve PFC-dependent function is consistent with evidence indicating ADHD is associated
with a dysregulation of fronto-striatal circuitry (for review, 24–29).
Combined, these observations indicate that psychostimulants exert diverse behavioral and
cognitive effects across a wide range of doses, with low and clinically-relevant doses
facilitating PFC-dependent behavior/cognition. The cognition-enhancing actions of low-
dose psychostimulants have been recently recognized by the general population, with rising
use of these drugs on and off college campuses to improve academic and work-related
performance by individuals without ADHD (30–32). Together, these observations indicate
that an animal model of ADHD is not necessary to examine the neural mechanisms involved
in the cognitive/therapeutic effects of low-dose stimulants. This is not a trivial advantage,
given most animal models of psychopathology suffer from a high degree of uncertainty
regarding the extent to which they model the neurobiology of a disorder, even when
mimicking certain behavioral features of that disorder.
Neurochemical Actions of Low-Dose Psychostimulants: Preferential
Targeting of PFC Catecholamines
Low and clinically-relevant doses of stimulants exert behavioral actions that are
qualitatively different than higher and behaviorally-activating doses. At higher doses,
psychostimulants block norepinephrine (NE) and dopamine (DA) reuptake, potently
increasing extracellular levels of NE and DA widely throughout the brain (33,34). Some
stimulants, particularly amphetamine, also actively stimulate DA efflux, an action believed
to involve entry of the drug into DA terminals and a reversal in the operation of the DA
transporter (35). Amphetamine can also stimulate NE efflux, though this only occurs at quite
high, and clinically-inappropriate doses (36). Finally, amphetamine can also block serotonin
reuptake, however, this too only occurs at relatively high and behaviorally-activating doses
(34). In contrast to amphetamine, methylphenidate acts only to block NE and DA reuptake,
neither inhibiting serotonin reuptake or stimulating NE or DA efflux (37).
Relative to higher doses of the psychostimulants, much less is known about the
neurobiology of cognition-enhancing doses of psychostimulants. However, the
neurochemical actions of psychostimulants reviewed above indicates that the cognition-
enhancing actions of low-dose psychostimulants are not dependent on an ability of these
drugs to block serotonin reuptake or actively stimulate catecholamine efflux. Moreover,
recent microdialysis studies demonstrate that low and clinically-relevant doses of these
drugs produce a preferential elevation in extracellular NE and DA within the PFC. Thus, in
rats, doses of methylphenidate that elicit clinically-relevant plasma concentrations and
improve PFC-dependent behavioral function (see Figure 1), produce prominent increases in
extracellular levels of NE and DA within the PFC, while having substantially smaller effects
on DA levels in the nucleus accumbens and NE levels in the medial septal area (see Figure
2; 20,21,38,39). This preferential targeting of PFC catecholamines is seen with both oral and
intraperitoneally-administered methylphenidate, as long as dose is adjusted to yield similar
plasma concentrations (21). Moreover, in both the hippocampus and somatosensory cortex,
these same doses of methylphenidate elevate NE levels similar to that seen in the medial
septal area and well below that observed in the PFC (20,38,39).
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Collectively, these observations indicate an enhanced sensitivity of PFC catecholamines to
cognition-enhancing doses of psychostimulants. This preferential sensitivity of PFC NE and
DA to low-dose stimulants may involve low DA transporter (DAT) levels within the PFC
combined with an ability of the NE transporter (NET) to clear extracellular NE and DA
(40,41). Thus, due to competition between NE and DA for binding to the NET, increases in
NE will result in less DA binding to the NET, resulting in an increase in extracellular DA
levels. Conversely, increases in extracellular DA will result in greater competition for NE
binding to the NET, resulting in an elevation in NE levels.
Do Psychostimulants Act within the PFC to Enhance Cognition?
The neurochemical effects of low-dose psychostimulants suggest the PFC may be an
important site of action in the cognition-enhancing actions of these drugs. Consistent with
this hypothesis, ongoing studies indicate that direct infusion of methylphenidate (0.5 μg/500
nl, but not 2.0 μg) into the dorsal anterior cingulate/dorsal prelimbic subfields of the medial
PFC of rats improves spatial working memory performance, comparable to that seen with
systemic administration (data not shown; Spencer and Berridge, unpublished observations).
Though preliminary, these observations suggest that action within the PFC is sufficient for
the cognition-enhancing actions of psychostimulants.
Although the PFC appears to be a principal site of action in the cognition-enhancing/
therapeutic effects low-dose psychostimulants, actions outside the PFC may well contribute
to the behavioral/cognitive effects of these drugs. Indeed, the 25–50% increase in
catecholamine levels observed outside the PFC with low-dose psychostimulant
administration is likely physiologically- and behaviorally-significant. Given the posited role
of frontostriatal circuits in both higher cognitive function and the pathophysiology of ADHD
(42–46), increased DA neurotransmission in select striatal regions may well contribute to the
behavioral effects of low-dose stimulants. PET imaging studies in humans indicate that
clinically-relevant doses of methylphenidate result in DAT occupancy within the nucleus
accumbens (47), consistent with results obtained in microdialysis studies (see above).
Current sensitivity limits of PET do not permit imaging of DAT or NET occupancy in PFC
or other cortical sites. However, the above-reviewed microdialysis studies suggest that
clinically-relevant doses of methylphenidate will result in a greater occupancy of DATs and
NETs in the PFC relative to the nucleus accumbens and other subcortical and cortical
regions.
Although MPH may act outside the PFC to produce therapeutic/cognitive actions, the fact
that low doses of stimulants produce only modest increases in NE/DA efflux in areas
associated with stimulant-induced motor activation (e.g. accumbens; 48–51) and arousal
(e.g. medial septum; 52,53) offers an explanation for why low doses of these drugs are
devoid of behavioral-activating and arousal-enhancing effects typically associated with the
psychostimulants. Moreover, the fact that low-dose stimulants exert only a modest impact
on circuitry thought to underlie the abuse liability of these drugs (i.e. accumbens DA; 49,50)
is consistent with evidence that indicates low-dose stimulants do not increase, and may
reduce, the liability for drug abuse in ADHD populations (54,55).
Modulatory Actions of Low-Dose Psychostimulants on Noradrenergic
Neuronal Discharge: Preservation of Phasic Discharge
The locus coeruleus (LC), provides the sole source of NE to the cortex and is implicated in a
variety of behavioral and cognitive processes including attention, working memory, and
decision making (for review, 17,56–58). LC neurons display both a spontaneous, or tonic
mode of discharge, and an evoked, or phasic, mode of discharge. Tonic discharge rates are
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causally related to arousal/wakefulness and the sensitivity of corticothalamic circuits to
sensory signals (for review, 56,59). Phasic LC discharge is observed in response to
behaviorally-relevant sensory stimuli, and is associated with decision/action (57) as well as
sensory signal processing (60,61). Suppressive actions of low-dose stimulants on tonic LC
discharge appear to be overcompensated by drug-induced elevations in extracellular NE (see
Figure 2). However, given the role of phasic LC discharge in the regulation of behavioral
actions, the behavioral/cognitive actions of low-dose stimulants could involve modulatory
actions on phasic LC discharge patterns.
In anesthetized rats, high-dose stimulants profoundly suppress LC discharge via activation
of somatodendritic α2-receptors (62,63). In contrast, low and cognition-enhancing doses of
methylphenidate only modestly suppress both tonic and phasic LC discharge in halothane-
anesthetized rats (Figure 3;64). Importantly, at these lower doses, the signal-to-noise ratio
for phasic vs. tonic LC discharge is largely unchanged (Figure 3). Phasic LC discharge is
related to tonic discharge rates, with both low and high tonic discharge rates associated with
weak phasic responses (for review, 56). Thus, it is important that in the halothane-
anesthetized rat, spontaneous discharge rates of LC neurons are similar to those seen in quiet
waking and LC neurons display robust phasic discharge to non-noxious sensory events (see
64).
The ability of low-dose stimulants to preserve the signal-to-noise ratio of phasic LC
discharge suggests that any information conveyed by a phasic burst of action potentials
superimposed on spontaneous discharge activity remains largely intact. Given the proposed
role of phasic LC discharge in higher behavioral/cognitive function (57), the fact that low-
dose stimulants preserve phasic LC signaling, as measured by the signal-to-noise ratio, is
likely behaviorally significant. From this perspective, the therapeutic actions of low-dose
psychostimulants may not stem directly from alterations in phasic LC discharge, but rather
may involve the fact that they largely leave intact phasic LC signaling.
When considering the potential functional impact of psychostimulant-induced changes in
LC discharge properties, a number of issues need to be considered. First, PFC-dependent
neuronal and behavioral function can be facilitated by pharmacological manipulations
directly within the PFC, such as intra-PFC infusions of NE/DA receptor agonists (see
below). These manipulations result in the sustained activation of NE/DA receptors in the
absence of direct actions on LC neurons. These observations indicate that sustained
activation of PFC NE receptors is sufficient to facilitate PFC-dependent behavior.
Second, monoamine neurotransmission within the cortex appears to involve two distinct
forms: synaptic transmission and extrasynaptic (or volume) neurotransmission. In the
traditional view of synaptic transmission, quantal neurotransmitter release from a
presynaptic terminal diffuses across a very short distance to receptors located within a
specialized region of a post-synaptic neuron (post-synaptic specialization). This arrangement
provides for a high-fidelity temporal coding of action potentials at the post-synaptic neuron.
However, in addition to this type of ‘synaptic’ neurotransmission, anatomical evidence
indicates that for NE and other monoamines, a large proportion of transmitter release sites
are not in close proximity to post-synaptic specializations. In this case, the transmitter acts
‘extrasynaptically’, relatively distant to the release site (65). With increasing diffusion
distance, the concentration associated with a bolus of neurotransmitter release decreases as
the neurochemical signal becomes more spatially diffuse. Thus, extrasynaptic
neurotransmission is not well-suited for the temporally-precise transmission of signals
associated with a phasic burst of 2–3 closely spaced LC action potentials.
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The microdialysis studies described above indicate that psychostimulants produce sustained
and large elevation in basal NE levels in the PFC combined with smaller increases in NE
outside the PFC. Thus, changes in NE levels driven by phasic LC discharge will be
superimposed on drug-induced elevations in basal NE concentrations, the magnitude of
which is regionally-dependent. In terms of extrasynaptic neurotransmission, it seems likely
that relatively large psychostimulant-induced increases in extrasynaptic NE levels in the
PFC will further dilute/mask phasic NE signaling associated with phasic LC discharge.
Consistent with this, recent voltammetric studies within somatosensory cortex demonstrate
that methylphenidate administration at a dose that produces relatively large increases in
extracellular NE levels within this region (5.0 mg/kg) does NOT increase phasic NE signals
and instead appears to decrease the amount of NE released per pulse (B.M. Willoughby, A.
Khair, B.D. Waterhouse, K.A. Moxon, unpublished observations).
In terms of synaptic transmission (involving juxtaposed pre-synaptic and post-synaptic
elements), it is possible that low-dose stimulants will comparably boost both basal NE
(driven by tonic LC discharge) and phasic NE levels, leaving the ratio of these two measures
unchanged. On the surface, this might be expected to maintain the functional impact of
phasic discharge. However, extensive evidence demonstrates that NE exerts non-monotonic
dose-dependent neuromodulatory actions (e.g. inverted-U shaped) the nature of which may
be at least partially dependent on the activity state of the post-synaptic neuron (56,66,67).
Thus, drug-induced elevations in basal NE (and DA) levels could shift the sensitivity of a
neuron to phasic NE signals and the direction of this shift could be either upward or
downward. Alternatively, electron microscopy studies suggest that the majority of
membrane-bound DATs and NETs are not associated with traditional synaptic contacts
(41,68). A sparsity of DAT/NET at the synapse would be expected to minimize the impact
of DAT/NET blockade on the magnitude of phasic signals within the synaptic cleft
(although, as reviewed above, tonic elevations in extracellular NE/DA may alter the
responsivity of the postsynaptic neuron to these phasic signals).
There are a variety of models that have examined potential functional consequences of
phasic and tonic LC discharge (69–71). However, for the purposes of the current discussion
it is sufficient to note that none of these take into account: 1) the contributions of
extrasynaptic vs. synaptic neurotransmission to the behavioral actions of tonic and phasic
LC discharge; 2) the actions of low-dose psychostimulants on tonic/phasic LC discharge
patterns that occur simultaneously with actions on tonic and phasic NE signaling across
synaptic and extrasynaptic modes of neurotransmission, and; 3) the differential impact of
low-dose stimulants on NE and DA levels/signaling across functionally-distinct
catecholamine terminal fields (e.g. PFC vs. extra-PFC regions).
Modulatory Actions of Low-Dose Psychostimulants on PFC Neuronal
Discharge: Facilitation of Signal Processing
Cognition-enhancing doses of psychostimulants produce relatively large increases in
extracellular NE and DA in the PFC and modest alterations in spontaneous and evoked
catecholamine neuronal discharge. For reasons outlined above, predicting the net influence
of these actions on PFC neuronal function is difficult. To better understand how low-dose
psychostimulants modulate PFC neuronal discharge properties, recent studies examined the
effects of cognition-enhancing doses of methylphenidate on spontaneous and evoked
discharge activity of PFC neurons in awake rats (6). In these studies, evoked discharge was
elicited via electrical stimulation of the ventral hippocampus. This work indicates that
cognition-enhancing doses of methylphenidate (0.5 mg/kg IP) increase the responsiveness of
PFC neurons to afferent signals while exerting minimal effects on spontaneous discharge
rates (Figure 4;6). Importantly, methylphenidate-induced increases in evoked responding are
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observed for both excitatory and inhibitory responses. The ability of low-dose stimulants to
enhance both excitatory and inhibitory afferent signals is consistent with the known
neuromodulatory actions of catecholamines (56, see below).
Consistent with the regionally-limited neurochemical actions of low-dose methylphenidate
described above (see Figure 2), this same dose of methylphenidate (0.5 mg/kg) does not
alter neuronal discharge properties of cortical neurons outside the PFC (i.e. within the
somatosensory cortex; 6). At modestly higher doses that fail to improve PFC-dependent
cognition (2.0 mg/kg), methylphenidate no longer increases the responsiveness of PFC
neurons but does alter somatosensory neuronal signal processing (39). In contrast to that
seen with cognition-enhancing doses, high and behaviorally-activating doses of
methylphenidate (15 mg/kg) produce a profound suppression of evoked discharge (~80%)
along with a modest suppression of spontaneous discharge (~20%) of PFC neurons (Figure
4;6). Therefore, at the single neuron level, low-dose methylphenidate elicits a preferential
and inverted-U shaped dose-dependent facilitation of evoked responding of PFC neurons.
The nature of this inverted-U dose response curve largely parallels the dose-dependent
actions of this drug on PFC-dependent behavior (Figure 1 vs. Figure 4).
Evidence indicates higher level behavior is dependent on the activity of large ensembles of
neurons. Thus, ultimately, it is important that we understand the modulatory actions of low-
dose stimulants at a neuronal ensemble level. Limited observations suggest that cognition-
enhancing doses of psychostimulants modulate the activity of ensembles of PFC neurons in
a manner that cannot be predicted solely from the actions observed at the single-neuron
level. Specifically, in the electrophysiological studies described above, the discharge activity
of multiple simultaneously recorded PFC neurons was analyzed using principal component
(PC) analyses. These analyses demonstrated that cognition-enhancing doses of
methylphenidate increase the dominant representation of afferent input to the PFC, as
measured by the first principal component (PC1), while reducing higher dimensional
patterns of distributed activity (PC2; 6). These neuronal ensemble-level actions also follow
an inverted-U shaped dose-response curve similar to that seen at the single-neuron level.
These observations provide proof-of-principle evidence that the cognition-enhancing actions
of psychostimulants may involve alterations in neural coding embedded within the discharge
activity of a population of PFC neurons.
Combined, these observations suggest that the cognitive/therapeutic effects of low-dose
psychostimulants involve a facilitation of signal processing abilities of PFC neurons and
PFC neuronal ensembles, potentially biasing neuronal responses to stronger and more salient
information. In contrast, the cognition-impairing effects of high-dose stimulants likely
involve a potent reduction in the signal processing abilities of PFC neurons. Consistent with
these observations, imaging studies demonstrate that cognition-enhancing doses of
stimulants increase task-related activity in the PFC of normal and ADHD subjects whereas
cognition-impairing doses suppress activity within the PFC (16,72,73).
Non-Stimulant Cognitive Enhancers Used in ADHD Also Facilitate
Catecholamine Neurotransmission Within the PFC
A number of drug classes has been demonstrated to be effective in the treatment of ADHD.
These include selective NE reuptake inhibitors (both tricyclic antidepressants and non-
tricyclic compounds), α2-agonists, and monoamine oxidase inhibitors. A comparison of the
neurobiological actions of these drugs with those of the psychostimulants provides important
information for better understanding key neural/pharmacological mechanisms that
contribute to the cognitive/therapeutic actions of ADHD-related treatments. This
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information should prove useful in the development of new treatments for ADHD and/or or
other conditions associated with PFC dysfunction.
1. Tricyclic Antidepressants and Selective NE Reuptake Inhibitors
Similar to the psychostimulants, tricyclic antidepressants are effective in the treatment of
ADHD (74). As a class, these drugs block monoamine reuptake, particularly NE and
serotonin (75). However, across the individual members of this class of drugs, there are
differences in selectivity for the different monoamine transporters. For example, while
imipramine displays high-affinity binding for both the serotonin and NE transporters,
desipramine and nortriptyline, are highly selective for the NE transporter (76). Importantly,
both desipramine and nortriptyline are effective in treating ADHD (77–81). Given selective
serotonin reuptake inhibitors are ineffective in the treatment of ADHD (74), these
observations suggest that the therapeutic actions of the tricyclic antidepressants involves
their ability to block NE reuptake.
Tricyclic antidepressants also bind to and block a variety of receptors, including
noradrenergic α1-, cholinergic, and histaminergic receptors. However, these actions are
typically viewed as contributing to the side effect profile of these drugs (e.g. anti-
cholinergic, cardiovascular, sedative effects; 75,78,82). Consistent with this view, relative to
the other tricyclic antidepressants, desipramine displays a lower affinity for many of these
receptors and is associated with a reduced side effect profile but not decreased efficacy in
the treatment of ADHD (74,77,78,83).
Atomoxetine is a non-tricyclic selective NE reuptake blocker. As with desipramine and
nortriptyline, atomoxetine is effective in the treatment of ADHD (13,84,85). Unlike the
tricyclic compounds, atomoxetine displays reduced affinity for neurotransmitter receptors
and thus is largely devoid of tricyclic-like side effects (82,86). Similar to the
psychostimulants, the cognitive/behavioral actions of atomoxetine are not limited to ADHD
having been documented in ‘normal’ human and animal subjects (87,88).
Despite the selectivity of desipramine and atomoxetine for the NET (relative to other
monoamine transporters), these compounds nonetheless increase extracellular levels of both
NE and DA in the PFC, while having minimal effects on DA levels outside the PFC (at least
in regions with low densities of NE fibers; 40,89). The ability of these selective NE reuptake
blockers to increase both NE and DA levels in the PFC is posited to reflect the fact that the
NET plays a prominent role in DA clearance in the PFC (see above, 40,90,91). However,
given stimulants are typically described as more effective in the treatment of ADHD and
stimulants block both NE and DA reuptake indicates that DA reuptake blockade and the
consequent elevation of DA levels outside the PFC (though modestly) likely contribute to
the therapeutic actions of psychostimulants.
2. α2-Agonists
NE acts at three families of adrenergic receptors, α1, α2, and β receptors, each comprised of
multiple subtypes. Across these families of NE receptors, α2 receptors display a higher
affinity for NE than α1 and β receptors (92). Of particular relevance for the current
discussion, there are three known subtypes of α2-adrenoceptors: α2A, α2B, and α2C (93). α2-
agonists have been well-documented to be efficacious in the treatment of ADHD (94, see
below for further discussion). As with the psychostimulants and selective NE-reuptake
inhibitors, these drugs improve PFC-dependent behavior in normal human and animal
subjects (95–103). Early observations demonstrated that α2 receptors are found pre-
synaptically on NE terminals where they act as autoreceptors, reducing rates of NE neuronal
discharge and NE release. The fact that α2 agonists reduce extracellular NE levels while
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stimulants and selective NE reuptake inhibitors have the opposite effect was initially
difficult to reconcile. A significant advance in our understanding of noradrenergic function
was the discovery that α2-receptors are located both pre- and postsynaptically (93).
Moreover, extensive evidence demonstrates that post-synaptic PFC α2-receptors, particularly
α2A-receptors, promote PFC-dependent cognition, strengthen synaptic inputs to PFC
neurons and enhance prefrontal network connectivity (104), all actions similar to those seen
with low-dose psychostimulants (6, see elsewhere in this Special Issue). Thus, the available
evidence suggests that the therapeutic and cognition-enhancing actions of α2-agonists result
from their ability to activation of post-synaptic α2A-receptors (see below for further
discussion).
3. Monoamine Oxidase Inhibitors
Though used less extensively than the other drug classes reviewed above, monoamine
oxidase inhibitors have been demonstrated to be effective in the treatment of ADHD
(74,105,106). By inhibiting the enzyme, monoamine oxidase, these drugs interfere with the
degradation of NE, DA and serotonin, increasing catecholamine/monoamine
neurotransmission. Low-dose deprenyl, a monoamine oxidase-B inhibitor, has been
suggested to have a reduced impact on norepinephrine relative to DA and serotonin (75).
Interestingly, low-dose deprenyl has been reported to be relatively ineffective in the
treatment of ADHD (74,79,105,107). Though speculative, these observations suggest the
efficacy of the monoamine oxidase inhibitors may be correlated with their ability to increase
NE neurotransmission.
Early work demonstrated that amphetamine inhibits monoamine oxidase (for review, 35).
Given the efficacy of monoamine oxidase inhibitors in ADHD, it was proposed that a
common action of drugs effective for ADHD was an inhibition of monoamine oxidase
(108). However, subsequent studies demonstrate that amphetamine-induced inhibition of
monoamine oxidase occurs only at relatively high doses inappropriate for clinical use (for
review, 35). Moreover, methylphenidate does not cross the cell membrane and thus cannot
gain access to monoamine oxidase. Thus, the therapeutic actions of psychostimulants are
unlikely to involve the inhibition of monoamine oxidase.
Behavioral and Electrophysiological Actions of Psychostimulants are
Similar to the Modulatory Actions of Catecholamine in the PFC
As reviewed above, a large body of evidence strongly indicates an important role for PFC
catecholamines in the cognition-enhancing/therapeutic actions of low-dose psychostimulants
and other drugs used in the treatment of ADHD. The anatomical, neuromodulatory and
behavioral actions of PFC catecholamines have been intensively studied for decades (see
elsewhere in this Special Issue; 42,58,109). Although an in-depth review of this topic
exceeds the scope of the current discussion, in this section we review evidence that suggests
receptor mechanisms that likely contribute to the cognition-enhancing and therapeutic
actions of psychostimulants and other ADHD-related drugs.
NE and DA brainstem nuclei extend efferents widely throughout the CNS (110). Consistent
with their diffuse projection systems, catecholamines have been demonstrated to modulate a
wide variety of behavioral and physiological processes via actions at a diversity of receptors
(56). The PFC contains all major receptor families for both NE (see above) and DA,
including D1 (comprised of D1 and D5 receptors) and D2 (comprised of D2, D3, and D4)
receptor families (58,111). It should be noted that the D4 receptor acts as a generalized
catecholamine receptor, binding both NE and DA (112).
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NE and DA exert an “inverted-U” shaped dose-dependent modulation of PFC-dependent
function, with either too little (e.g. drowsy) or too much (e.g. stress) associated with an
impairment in PFC-dependent function (113). The pharmacology of PFC-dependent
behavior has been most extensively studied using delayed-response tasks of working
memory (similar to those used to characterize the cognition-enhancing actions of low-dose
psychostimulants reviewed above). Hallmark features of these tasks include the use of short
delay intervals and a sensitivity to the debilitating effects of distractors and stress (see, 114).
As reviewed above, stimulation of postsynaptic α2A receptors in the PFC promotes
performance in these tasks (for review, 113,115). In contrast, pharmacological stimulation of
PFC α1-receptors produces a stress-like impairment, while blockade of PFC α1-receptors
prevents stress-related impairment in performance in these tasks (113,116,117).
Based on these and other observations, it has been hypothesized that at lower rates of NE
release higher affinity post-synaptic α2 receptors are engaged, promoting PFC-dependent
function, while at higher rates of NE release, associated with stress, lower affinity α1-
receptors contribute to stress-related impairment in PFC function (for review, 113). The
differential activation of postsynaptic α2 vs. α1 receptors across varying rates of NE release
results in an inverted-U shaped modulation of PFC-dependent behavior. Limited evidence
suggests opposing actions of PFC β1 and β2 receptors on PFC-dependent behavior, with β1
receptors associated with impairment and β2 receptors associated with modest
improvements in delayed-response tasks of working memory (118,119). The net
contribution of these opposing actions of β1 and β2 receptors to psychostimulant-induced
alterations in PFC-dependent behavior is unclear. In the case of DA, the inverted-U shaped
modulation of PFC-dependent behavior involves, in part, inverted-U shaped actions of D1
receptors, with both low and high rates of D1 receptor stimulation associated with impaired
PFC function (113,120).
One of the most intensively studied aspects of PFC neurophysiology is the sustained
discharge displayed by a subset (approximately 30%) of PFC neurons during the delay-
portion of delayed-response tasks (121). In the dorsolateral PFC of monkeys, delay-related
discharge displays spatial tuning, with largest delay-related neuronal responses observed to
stimuli within a restricted spatial location (122). Anatomically, α2A and D1 receptors appear
to be located on separate dendritic spines on PFC pyramidal cells. This anatomical
segregation of receptors offers the potential for these two receptor subtypes to differentially
modulate qualitatively distinct afferent signals that arise from distinct neuronal populations
(104,123). Indeed, electrophysiological evidence indicates that α2A receptor stimulation
strengthens behaviorally appropriate inputs, strengthening delay-related discharge for
stimuli in the preferred spatial location, while D1 receptor stimulation weakens
inappropriate inputs, reducing delay-related discharge to stimuli located in non-preferred
spatial locations (113,120). Combined, these actions improve the spatial tuning properties of
PFC neurons. In contrast, α1-receptor stimulation or high rates of D1 receptor stimulation
produce a general suppression of PFC neuronal activity, reducing spatial tuning properties
(104,117).
Not all PFC-dependent tasks are impaired by PFC α1-receptor activation. Specifically, in
rodents extra-dimensional attentional set-shifting is facilitated by intra-PFC infusion of α1-
receptor agonists (124). Nonetheless, α2A-agonists are used in the treatment of ADHD and
these drugs improve performance in delayed alternation tasks but not in attentional set-
shifting tasks (124). Thus, there is a close alignment between the pharmacology of the
cognition-enhancing and therapeutic actions of drugs used in the treatment of ADHD and
the pharmacology of delayed-alternation tasks of working memory, but not attentional set-
shifting. Combined, these observations suggest that in terms of preclinical studies focused
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on the pharmacology of ADHD, delayed-alternation tasks of working memory appear a
more appropriate behavioral assay than attentional set-shifting tasks.
Cognition-Enhancing Actions of Low-Dose Stimulants Involve NE α2 and
DA D1 receptors
The available evidence suggests the cognition-enhancing actions of low-dose
psychostimulants involve drug-induced increases in signaling at PFC α2 and/or D1
receptors. Consistent with this hypothesis, the ability of low-dose methylphenidate to
improve PFC-dependent behavior, as measured in delayed-response tasks, is prevented by
systemically administered α2 and D1 antagonists (at doses that have no impact on baseline
cognitive function; 5). These observations suggest that the cognition-enhancing effects of
low-dose psychostimulants are dependent on both α2 and D1 receptors located within the
PFC.
Moreover, preliminary data indicate that NE α2 and DA D1 receptor antagonists prevent
atomoxetine-induced improvement in PFC-dependent behavior (AFT Arnsten, unpublished
observations), similar to that seen with the psychostimulants. Interestingly, although
mianserin, a tetracyclic antidepressant, acts as a selective NE reuptake inhibitor (relative to
other monoamines), this compound is not effective in treating ADHD (125). An important
difference between mianserin and other selective NE reuptake inhibitors used to treat
ADHD (desipramine, nortriptyline, atomoxetine), is that mianserin acts as a relatively high
affinity α2-antagonist and thus will block postsynaptic α2A receptors (75). Combined, the
available evidence indicates that the therapeutic/behavioral actions of low-dose stimulants
and selective NE-reuptake blockers involve increased signaling at NE α2 and DA D1
receptors in the PFC.
Do Psychostimulants Target the Underlying Etiology of ADHD?
The above-reviewed information suggests a prominent role of NE and DA in the
pharmacology of ADHD. This is often interpreted as suggesting a role for NE and/or DA in
the etiology of this disorder. However, it is important to note that treatments can be
therapeutic while not targeting the biological origins of a disorder. As reviewed above,
catecholamines act as neuromodulators, modifying the sensitivity of neurons to afferent
signals. Available evidence suggests that the therapeutic actions of low-dose stimulants and
other cognitive enhancers used to treat ADHD involve drug-induced modulation of modestly
dysregulated PFC neuronal circuits via actions of PFC catecholamine receptors.
Theoretically, this action could occur even if PFC dysregulation arises from mechanisms
independent of catecholamine signaling. For example, if ADHD is associated with a
dysregulation in PFC network connections, due to impaired development or other
mechanisms, PFC α2A and D1 receptors may well continue to facilitate PFC neuronal signal
processing and PFC-dependent behavior. Given this, the fact that stimulants are effective in
the treatment of ADHD does not necessarily indicate that ADHD involves dysfunctional
catecholamine signaling.
Nonetheless, given ADHD is highly heritable and pharmacological treatments for ADHD
enhance catecholamine neurotransmission, there has been substantial interest in the degree
to which catecholamine-related genes may contribute to this disorder. Numerous studies
have identified multiple catecholamine-related gene alleles that are associated with ADHD,
including NE and DA receptors, DA and NE transporters and the NE synthetic enzyme,
dopamine β-hydroxylase (126–128). Genetic insults to dopamine beta hydroxylase are of
interest, as they reduce NE production and have been associated with weaker sustained
attention, impaired PFC executive function, and increased impulsivity (129,130).
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Despite these statistically significant genetic associations with ADHD, it is important to note
that, in general, the variance in this disorder explained by any one of these genes is
extremely small, often explaining no more than a few percent of variance (see 131).
Additionally, evidence suggests that at least some of these genes may function as modifier
genes, modifying rather than driving the behavioral phenotype of ADHD (see 132).
Although these considerations do not rule out an involvement of catecholamine-related
genes in ADHD, they suggest that, individually, the majority of these genes are unlikely to
play a major role in the etiology of ADHD.
Synthesis and Future Directions
Low-dose psychostimulants facilitate a variety of behavioral and cognitive processes
dependent on the PFC. These behavioral/cognitive actions are in stark contrast to the
behaviorally-activating and cognition-impairing effects of higher doses of these drugs.
Importantly, the cognition-enhancing and behavioral-calming properties of low-dose
psychostimulants are not limited to ADHD: these drugs exert similar actions in both normal
human and animal subjects.
Research over the past ten years has provided significant insight into the neurobiological
mechanisms that support the cognition-enhancing and therapeutic actions of low-dose
psychostimulants. This work indicates that cognition-enhancing doses of psychostimulants
preferentially increase extracellular levels of catecholamines in the PFC while preserving
phasic signaling of catecholamine neurons. The regionally-selective neurochemical actions
of low-dose psychostimulants are in distinct contrast to the widespread actions of higher and
behaviorally-activating doses of these drugs. At clinically-relevant doses, psychostimulants
also exert a regionally-specific enhancement of neuronal responding to afferent signals
within the PFC. This regionally-specific facilitatory effect on PFC neuronal signal
processing contrasts with the more widespread electrophysiological actions seen with
moderately higher doses as well as the profound suppression of PFC neuronal signaling seen
with high-dose psychostimulants. These observations suggest a prominent role of PFC
catecholamines in the behavioral/therapeutic actions of low-dose psychostimulants.
Consistent with this, preliminary observations suggest intra-PFC infusion of low-dose
psychostimulants facilitate PFC-dependent behavior similar to that seen with systemic
administration.
Considerable evidence indicates that the cognition-enhancing/therapeutic actions of low-
dose psychostimulants and other drugs used to treat ADHD are dependent on D1 and/or α2
receptors within the PFC. This includes the similarity between the behavioral and
electrophysiological actions of low-dose stimulants and the behavioral and
electrophysiological actions of postsynaptic PFC α2 and D1 receptors. Moreover, the
cognitive/behavioral effects of low-dose stimulants are blocked by systemically
administered α2 and D1 antagonists. Although there has been a tendency in the literature to
emphasize the potential role of DA in the therapeutic actions of low-dose stimulants, DA is
neither the primary target of these drugs, nor the sole participant in their cognitive/
behavioral actions. Combined, the available evidence strongly indicates that the cognition-
enhancing/therapeutic actions of low-dose psychostimulants involve both NE and DA acting
at postsynaptic α2 and D1 receptors in the PFC.
There is substantial similarity between the behavioral and neurobiological actions of low-
dose psychostimulants and other major classes of drugs used in the treatment of ADHD.
This includes the ability of, psychostimulants, selective NE reuptake inhibitors (desipramine
and atomoxetine) and α2 agonists to improve PFC-dependent function in ADHD patients as
well as normal human and animal subjects. Additionally, as with the psychostimulants,
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selective NE reuptake inhibitors elevate both NE and DA in the PFC. Finally, for all major
classes of drugs used in the treatment of ADHD, the behavioral/cognitive effects of these
drugs are dependent on D1 and/or α2 receptors.
Despite the hypothesized role of the PFC in the therapeutic actions of ADHD, drug actions
outside the PFC may nonetheless be important for maximal therapeutic/cognitive benefit. A
better understanding of the neurocircuitry involved in the cognitive/therapeutic effects of
psychostimulants and other drugs used in the treatment of ADHD is an important issue for
future studies.
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Low-dose psychostimulants elicit an inverted-U shaped dose-dependent modulation of PFC-
dependent behavior. Shown are the effects of varying doses of intraperitoneally
administered methylphenidate on performance in a delayed-response task of spatial working
memory. Methylphenidate improves performance in this task at doses that produce similar
and clinically-relevant plasma concentrations (0.5 mg/kg; orally; 21). At higher doses,
performance is impaired, resulting in an inverted-U shaped dose response curve. In this task,
animals were rewarded (chocolate chip) for entering the arm of a t-maze not entered on the
previous trial. Between trials animals were held in a start box for a delay (range = 10–120
secs) titrated so that baseline accuracy is 70–80%. Baseline performance was defined as the
average performance from the two days immediately preceding drug testing. A similar
facilitation of performance in this task was observed with oral administration of a cognition-
enhancing dose of methylphenidate that produced plasma concentrations comparable to
those seen with intraperitoneal administration of 0.5 mg/kg methylphenidate (2.0 mg/kg;
21). Data are mean performance (± SEM) across the 10 trials, expressed as percent
correct. *P < 0.01 relative to baseline performance. Modified from (6,21).
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Cognition-enhancing doses of methylphenidate increase extracellular NE and DA
preferentially within the PFC. Shown are the effects of a cognition-enhancing dose of MPH
that produces clinically-relevant peak plasma concentrations (0.5 mg/kg, intraperitoneally)
on extracellular levels of NE and DA in the PFC, NE in the medial septal area (MSA), and
DA in the nucleus accumbens core (ACC). Data are an average of two 15-minute samples
colleted 15–45 minutes following drug treatment and are expressed as percent of vehicle-
treatment. At this dose, MPH produced only a modest (~30%) increase in NE and DA levels
outside the PFC. In contrast, within the PFC, this dose of MPH produced a substantially
larger increase in NE and DA levels. Moreover, the increase in PFC NE levels (~200%) was
significantly larger than that seen for PFC DA (~85%). A similar pattern of effects was
observed with oral administration of a cognition-enhancing dose (2.0 mg/kg) of
methylphenidate that produced plasma concentrations comparable to those seen with
intraperitoneal administration of 0.5 mg/kg methylphenidate. *P < 0.001 relative to MSA
NE; +P < 0.001 relative to PFC DA, #P < 0.05 relative to ACC DA. Modified from (21).
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Cognition-enhancing doses of methylphenidate exert a modest influence on tonic and phasic
LC discharge. Shown are the effects of varying doses of methylphenidate (intraperitoneally)
on the magnitude of LC phasic discharge in the halothane-anesthetized rat (see 64). Doses
examined included the cognition-enhancing dose of 0.5 mg/kg. Evoked discharge was
elicited by brief electrical stimulation of the foot. For all treatments, data were normalized
by calculating the percent change from pre-drug conditions and then expressed as a change
from vehicle (saline). Panel A depicts the effects of low-dose methylphenidate on the
magnitude of phasic LC discharge, expressed as a change from saline treatment, for a 15-
minute epoch that began 15-minutes following drug treatment (n=60 stimulus presentations).
Methylphenidate produced a dose-dependent decrease in phasic discharge that was relatively
mild at the 0.5 mg/kg dose. Panel B depicts the effects of methylphenidate on the signal-to-
noise ratio of phasic responses (relative to tonic discharge). Because methylphenidate-
induced suppression of phasic discharge was associated with a similar magnitude
suppression of tonic discharge, methylphenidate had minimal effects on the signal-to-noise
ratio for phasic discharge, particularly at the 0.5 mg/kg dose. Similar effects were observed
with oral methylphenidate administration (see 64). *P < 0.05, **P < 0.01 relative to saline-
controls. Modified from (64).
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Cognition-enhancing doses of methylphenidate preferentially increase the responsiveness of
PFC neurons. Shown are the effects of varying doses of methylphenidate on spontaneous
discharge and excitatory evoked-responses (elicited by brief electrical stimulation of the
hippocampus) of PFC neurons in the awake-freely moving rat. Doses examined included the
cognition-enhancing dose of 0.5 mg/kg (see 6). All data are expressed as the percent change
from pre-drug conditions. Panel A: Spontaneous discharge of PFC neurons was minimally
affected by low doses of methylphenidate. Panel B: Hippocampal stimulus-evoked
excitatory discharge in PFC neurons exhibited a dose-dependent inverted-U facilitation/
suppression. The maximal facilitation of PFC responses to hippocampal input was observed
following the 0.5 mg/kg dose. A behaviorally-activating, dose of MPH (15.0 mg/kg)
resulted in a suppression of stimulus-evoked activity well below baseline levels. *P <
0.05, **P < 0.01 relative to baseline. Modified from (6).
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